Helen Torley, PRESIDENT AND CEO at HALOZYME THERAPEUTICS, INC. (HALO), sold 89,600 shares at $73.70 ($6.6M) on 2025-09-02, disclosed to the SEC on 2025-09-04.
Scheduled sale ($6.6M) by PRESIDENT AND CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.49 | 300 | $22K | 0.3% |
| 2 | $73.70 | 16,288 | $1.2M | 18.1% |
| 3 | $73.70 | 16,288 | $1.2M | 18.1% |
| 4 | $74.15 | 3,412 | $253K | 3.8% |
| 5 | $74.15 | 3,412 | $253K | 3.8% |
| 6 | $74.22 | 9,500 |
| $705K |
| 10.6% |
| 7 | $74.63 | 10,500 | $784K | 11.8% |
| 8 | $73.54 | 9,900 | $728K | 11.0% |
| 9 | $73.54 | 9,900 | $728K | 11.0% |
| 10 | $74.33 | 7,800 | $580K | 8.7% |
| 11 | $75.22 | 2,300 | $173K | 2.6% |
| Total | $73.95 avg | 89,600 | $6.6M | 100% |
| Filing → |
| HALO | SELL | 2026-07-09 | $153K | — | Filing → |
| HALO | SELL | 2026-06-03 | $3.4M | — | Filing → |
| HALO | SELL | 2026-05-13 | $3.4M | — | Filing → |